MXPA03009553A - Uso de acido biliar o conjugados de acidos grasos de sales biliares. - Google Patents

Uso de acido biliar o conjugados de acidos grasos de sales biliares.

Info

Publication number
MXPA03009553A
MXPA03009553A MXPA03009553A MXPA03009553A MXPA03009553A MX PA03009553 A MXPA03009553 A MX PA03009553A MX PA03009553 A MXPA03009553 A MX PA03009553A MX PA03009553 A MXPA03009553 A MX PA03009553A MX PA03009553 A MXPA03009553 A MX PA03009553A
Authority
MX
Mexico
Prior art keywords
bile
acid
fatty acid
bile salt
salt fatty
Prior art date
Application number
MXPA03009553A
Other languages
English (en)
Inventor
Gilat Tuvia
Original Assignee
Galmed Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Int Ltd filed Critical Galmed Int Ltd
Publication of MXPA03009553A publication Critical patent/MXPA03009553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere al uso de un acido biliar o conjugado de acido graso de la sal biliar de la formula general II, W-X-G, en la cual G es un acido biliar o el radical de la sal biliar, el cual si se desea, es conjugado en la posicion 24 con un aminoacido adecuado, W representa uno o dos radicales de acidos grasos que tienen 14-22 atomos de carbono, y X representa un elemento de enlace adecuado o un enlace C=C directo entre el acido biliar o el radical de la sal biliar, y el (los) acido(s) graso(s), o una composicion farmaceutica que comprende los mismos para la reduccion del colesterol en la sangre, para la reduccion del colesterol en la sangre, para el tratamiento de Esteatosis Hepatica, Hiperglicemia y Diabetes.
MXPA03009553A 2001-04-17 2002-04-15 Uso de acido biliar o conjugados de acidos grasos de sales biliares. MXPA03009553A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (1)

Publication Number Publication Date
MXPA03009553A true MXPA03009553A (es) 2004-05-24

Family

ID=11075322

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009553A MXPA03009553A (es) 2001-04-17 2002-04-15 Uso de acido biliar o conjugados de acidos grasos de sales biliares.

Country Status (24)

Country Link
US (2) US7501403B2 (es)
EP (2) EP1379254B1 (es)
JP (1) JP4324706B2 (es)
KR (1) KR100883080B1 (es)
CN (1) CN1259918C (es)
AT (2) ATE365044T1 (es)
AU (2) AU2002307771B2 (es)
BR (1) BR0208924A (es)
CA (2) CA2444266C (es)
CY (1) CY1106853T1 (es)
CZ (2) CZ300489B6 (es)
DE (2) DE60232559D1 (es)
DK (2) DK1790346T3 (es)
EA (1) EA007565B1 (es)
ES (2) ES2328966T3 (es)
HU (1) HU230548B1 (es)
IL (1) IL142650A (es)
MX (1) MXPA03009553A (es)
NO (2) NO333910B1 (es)
NZ (1) NZ528868A (es)
PL (2) PL205057B1 (es)
PT (2) PT1790346E (es)
UA (1) UA78699C2 (es)
WO (1) WO2002083147A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
WO2009013334A1 (en) * 2007-07-25 2009-01-29 Medizinische Universität Graz Use of nor-bile acids in the treatment of arteriosclerosis
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
EA022631B1 (ru) * 2009-01-12 2016-02-29 Байокир Инк. Лекарственная форма, содержащая масляную кислоту или глутамин, и способ лечения состояния с повышенным уровнем глюкозы у субъекта
WO2010086864A1 (en) 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
MX2014013150A (es) 2012-05-01 2015-05-11 Catabasis Pharmaceuticals Inc Conjugados de acidos grasos de estatina y agonistas fxr, composiciones y metodos de uso.
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
US10702546B2 (en) 2012-11-29 2020-07-07 St Pharm Co., Ltd. Bile acid oligomer conjugate for novel vesicular transport and use thereof
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
WO2015083164A1 (en) * 2013-12-04 2015-06-11 Galmed Research & Development Ltd. Aramchol salts
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
AU2015270099A1 (en) * 2014-06-01 2016-12-15 Galmed Research And Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
US10849911B2 (en) 2015-06-10 2020-12-01 Galmed Research And Development Ltd. Low dose compositions of Aramachol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) * 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤

Also Published As

Publication number Publication date
NO20034609D0 (no) 2003-10-15
AU2002307771B2 (en) 2006-10-19
ES2328966T3 (es) 2009-11-19
CZ300489B6 (cs) 2009-06-03
PT1790346E (pt) 2009-09-04
EP1790346B1 (en) 2009-06-03
CN1259918C (zh) 2006-06-21
CA2703688C (en) 2012-07-31
UA78699C2 (en) 2007-04-25
CZ2008296A3 (es) 2004-04-14
AU2007200191A1 (en) 2007-02-08
HUP0400801A2 (hu) 2004-08-30
US20090149537A1 (en) 2009-06-11
EP1790346A3 (en) 2007-08-22
NO333910B1 (no) 2013-10-14
EA007565B1 (ru) 2006-12-29
DE60220775T2 (de) 2008-03-06
NO20131219L (no) 2003-11-28
EP1379254B1 (en) 2007-06-20
CA2703688A1 (en) 2002-10-24
CZ309042B6 (cs) 2021-12-22
KR100883080B1 (ko) 2009-02-10
WO2002083147A1 (en) 2002-10-24
ATE432705T1 (de) 2009-06-15
NZ528868A (en) 2005-09-30
CA2444266A1 (en) 2002-10-24
DE60220775D1 (de) 2007-08-02
EP1790346A2 (en) 2007-05-30
NO335087B1 (no) 2014-09-08
NO20034609L (no) 2003-11-28
HUP0400801A3 (en) 2012-09-28
HU230548B1 (hu) 2016-11-28
US20040121993A1 (en) 2004-06-24
JP2004525962A (ja) 2004-08-26
JP4324706B2 (ja) 2009-09-02
PL205057B1 (pl) 2010-03-31
DK1379254T3 (da) 2007-10-15
IL142650A (en) 2007-06-03
ES2289137T3 (es) 2008-02-01
BR0208924A (pt) 2004-04-20
CY1106853T1 (el) 2012-05-23
US7501403B2 (en) 2009-03-10
AU2007200191B2 (en) 2008-09-04
PL366585A1 (en) 2005-02-07
PT1379254E (pt) 2007-07-10
CZ20032710A3 (cs) 2004-04-14
ATE365044T1 (de) 2007-07-15
EA200301017A1 (ru) 2005-04-28
CN1529603A (zh) 2004-09-15
PL211438B1 (pl) 2012-05-31
KR20030092063A (ko) 2003-12-03
DE60232559D1 (de) 2009-07-16
IL142650A0 (en) 2002-03-10
EP1379254A1 (en) 2004-01-14
CA2444266C (en) 2010-07-27
US8110564B2 (en) 2012-02-07
DK1790346T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
MXPA03009553A (es) Uso de acido biliar o conjugados de acidos grasos de sales biliares.
CA2325933A1 (en) Fatty acid derivatives of bile acids and bile acid derivatives
WO2003022208A3 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
EP1196444B8 (en) Exendin-4 conjugates and their medical use
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
LT2003002A (en) A soluble ctla4 molecule for use in the treatment rheumatic diseases
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
AU2002351593A1 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
JP2004525962A5 (es)
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2002038566A3 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment

Legal Events

Date Code Title Description
FG Grant or registration